Therapeutics Solutions International Signs Agreement With Beijing Regenesis Biotechnology to License and Develop Patent for Anti-aging Use of Cord Blood Plasma and NanoStilbene

Company Expands Use of Commercially Available Anti-Inflammatory Nanoparticle Nutraceutical NanoStilbene™ into Anti-Aging Market

NEWS PROVIDED BY
Therapeutic Solutions International, Inc.
Nov 11, 2019, 09:00 ET

OCEANSIDE, California, Nov. 11, 2019 /PRNewswire/ — Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today the signing of a Letter of Intent with Beijing Regenesis Biotechnology Co. Ltd., of Beijing China to develop and commercialize the anti-aging properties of cord blood plasma combined with NanoStilbene.

“Our Company is the leading entity in implementation of anti-aging regenerative medicine in China. We have previously commercialized novel technologies for rejuvenation of testicular and ovarian function,” said Dr. Fei Li, Chief Executive Officer of Beijing Regenesis. “Cord blood components have been used for more than a Century in medicine with an excellent safety profile. We are excited to utilize the new technology developed by TSOI in order to reduce and potentially even reverse the biological aspects of aging.”

“Having previously collaborated with Beijing Regenesis, I am excited to expand our work in the area of anti-aging medicine. There are publications from Stanford University[1] and Harvard University[2] that have shown that if the circulation of an aged mouse is connected to the circulation of a young mouse, various factors secreted by young mice induce an anti-aging/rejuvenating effect on organs/tissues of aged mice. Following this logic, other studies have demonstrated that human cord blood plasma, when administered to aged mice results in restoration of brain function and improved cellular function in the hippocampus[3],” said Dr. Feng Lin, Chief Scientific Officer of TSOI. “We are very excited to commercialize the use of cord blood plasma with NanoStilbene as a means of translating the animal parabiosis experiments into humans.”

“Our Company is about fast forwarding the development of novel medical technologies. Based on the reputation, success, and ingenuity of Beijing Regenesis, we believe we have found an ideal commercialization partner,” said Timothy Dixon, President and Chairman of TSOI. “We are especially grateful for Congressional Candidate Famela Ramos, our Director of Business Development, for having arranged our meeting and providing an excellent venue for signing of the Letter of Intent.”

About Therapeutic Solutions International, Inc.
Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one’s immune system. The Company’s corporate website is www.therapeuticsolutionsint.com and e-commerce at www.youcanordernow.com.

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings. To the extent that statements in this press release are not strictly historical, including statements as to product launch timing, revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future collaboration agreements, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

References:

[1] Conboy et al. Rejuvenation of aged progenitor cells by exposure to a young systemic environment. Nature. 2005 Feb 17;433(7027):760-4. https://www.ncbi.nlm.nih.gov/pubmed/15716955

[2] Katsimpardi et al. Vascular and neurogenic rejuvenation of the aging mouse brain by young systemic factors. Science. 2014 May 9;344(6184):630-4. https://www.ncbi.nlm.nih.gov/pubmed/24797482

[3] Castellano et al. Human umbilical cord plasma proteins revitalize hippocampal function in aged mice. Nature 2017 Apr 27;544(7651):488 492.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586222/

CONTACT INFORMATION

Therapeutic Solutions International, Inc.
ir@tsoimail.com

SOURCE Therapeutic Solutions International, Inc.